MOTS-c

Overview

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded inside mitochondrial DNA. First described in 2015, it acts as a signaling molecule that helps coordinate how cells produce and use energy, largely by activating the AMPK pathway and, under metabolic stress, moving into the nucleus to influence gene expression. Because its natural levels rise with physical activity, it is frequently described as an 'exercise mimetic.'

Evidence Quality

The strongest data come from cell and rodent studies, where MOTS-c improves insulin sensitivity, supports healthy glucose and fat metabolism, and, in older mice, restored physical capacity. Human evidence is far thinner and mostly observational, showing that circulating and muscle MOTS-c levels track with exercise, metabolism, and muscle composition. A synthetic analog (CB4211) reached early-phase human trials for metabolic disease, but MOTS-c itself has no completed controlled efficacy trials. On a simple A-to-D scale this sits around C.

What the Research Shows

In animals, MOTS-c has reduced diet-induced weight gain and insulin resistance and improved metabolic flexibility, and a single dose improved acute exercise performance in some models. In humans, muscle MOTS-c increases after long-term physical activity, and higher levels have been associated with greater muscle mass and function. These findings are promising but do not establish that injecting MOTS-c produces the same benefits in people.

Dosage Notes

There is no established clinical dose. Community and research protocols commonly use roughly 5 to 10 mg per week, split into two or three subcutaneous injections, run in blocks of about four to six weeks. Some users time doses around training. These figures come from anecdote and vendor guides, not from trials.

Who Should Be Cautious

Because MOTS-c affects AMPK and glucose handling, anyone using metformin or other glucose-lowering agents should be careful, as effects may add up. Its role in cancer-related signaling is unresolved, so it is generally avoided by people with active or recent cancer. It should not be used in pregnancy or while breastfeeding, and it is banned by WADA for competitive athletes.

Availability

MOTS-c is sold by research-chemical suppliers as a lyophilized powder for reconstitution, not as an approved medicine. It is commonly offered in 10 mg and 20 mg vials (3 mL glass); the 10 mg vial is a common starting size. Purity and labeling vary between vendors, so a certificate of analysis is worth checking.

Bottom Line

MOTS-c is an interesting mitochondrial peptide with solid preclinical support for metabolism, energy, and healthy aging, plus suggestive human association data. It is not FDA-approved, human safety and efficacy data are limited, and all use remains experimental and research-only.